WO2010103544A4 - A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants - Google Patents

A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants Download PDF

Info

Publication number
WO2010103544A4
WO2010103544A4 PCT/IN2010/000137 IN2010000137W WO2010103544A4 WO 2010103544 A4 WO2010103544 A4 WO 2010103544A4 IN 2010000137 W IN2010000137 W IN 2010000137W WO 2010103544 A4 WO2010103544 A4 WO 2010103544A4
Authority
WO
WIPO (PCT)
Prior art keywords
release
sustained release
oral sustained
hours
polymers
Prior art date
Application number
PCT/IN2010/000137
Other languages
French (fr)
Other versions
WO2010103544A3 (en
WO2010103544A2 (en
Inventor
Dinesh Shantilal Patel
Sachin Dinesh Patel
Shashikant Prabhudas Kurani
Original Assignee
Dinesh Shantilal Patel
Sachin Dinesh Patel
Shashikant Prabhudas Kurani
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dinesh Shantilal Patel, Sachin Dinesh Patel, Shashikant Prabhudas Kurani filed Critical Dinesh Shantilal Patel
Priority to CN2010800196712A priority Critical patent/CN102438597A/en
Priority to EP10740754A priority patent/EP2405900A2/en
Priority to EA201171109A priority patent/EA201171109A1/en
Publication of WO2010103544A2 publication Critical patent/WO2010103544A2/en
Publication of WO2010103544A3 publication Critical patent/WO2010103544A3/en
Publication of WO2010103544A4 publication Critical patent/WO2010103544A4/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Abstract

The disclosed invention provides novel sustained release pharmaceutical preparations and process for making such compositions of Tolperisone and/or Eperisone and/or a pharmaceutically acceptable salt thereof. The present invention provides a sustained release formulation of Tolperisone and Eperisone either single or in combination or otherwise in combination with other drugs selected from the classes such as analgesic, antipyretic, neuroprotective agents, other muscle relaxants which can be formulated either in a fixed dose or as combination kit for oral administration. The composition is suitable for once a day administration into mammals and provides sustained and prolonged drug release till 24 hours which helps to reduce dosing frequency. The composition comprises therapeutically effective amount of active substance, release retarding polymers and other pharmaceutically acceptable excipients.

Claims

AMENDED CLAIMS received by the International Bureau on 11 April 2011 (11.04.2011)
1. A novel oral sustained release composition which comprises of therapeutically effective amount of active ingredient selected from Tolperisone and Eperisone and mixtures thereof in combination with therapeutically effective concentration of Tramadol or Etodolac or Amtolmetin or combination of any of these drugs or in combination with the drugs selected from muscle relaxants, analgesics, antipyretics or non steroidal anti inflammatory drugs. and further comprising pharmaceutical excipients including release retarding excipient(s) adapted to achieve drug release over a period of 24 hours, during which 20 to 80% of the active ingredient is dissolved between 2 to 8 hours, and that of about 80% of active ingredient is dissolved between 8 and 24 hours, when formulated in suitable dosage form, wherein the active ingredient (s) and the release retarding excipient(s) are present in the ratio of 1 : 0.5 to 1 :3.
2. An oral sustained release composition as claimed in claim , wherein said drug is in the form selected from the group consisting of a raw powder, dispersed in a suitable liquid, micro or nano particles, micro or a solvated powder, semisolid, a tablet, a capsule or a suitable specific two- or three-dimensional matrix composition.
3. An oral sustained release formulation according to claim 1 , wherein the pharmaceutical excipients is selected from the group of pharmaceutical binders, diluents, release retarding excipients, lubricant, glidants, buffering agent, gas generating agents, coating systems, solvents, coloring agents.
4. An oral sustained release composition according to claim 1 comprising a pharmaceutical gastro-retentive delivery system containing Tolperisone or Eperisone or or salts thereof or other muscle relaxants or combinations thereof adapted to remain floated in the gastric medium up to 24 hours for controlled release of therapeutically active agent in stomach or upper part of gastrointestinal tract.
5. The delivery system as claimed in claim 4, further comprising at least one gas- generating agent.
6. An oral sustained release formulation according to claim 1 , wherein the pharmaceutical excipients are used about 30 to 75% by weight.
7. An oral sustained release formulation according to claim 1 and claim 3, release retarding excipients are selected from group of hydrophilic and hydrophobic polymers.
8. The oral sustained release composition as claimed in claim 7 wherein the release retarding excipients are selected from
a) Cellulose derivatives including methylcellulose, ethyl cellulose, hydroxomethylcellulose, different viscocity grades of hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethylcellulose, carboxymethylcellulose;
b) Hydrophilic polymer selected from the group consisting of a protein, a polysaccharide, , a hydrogel, polyvinyl alcohol or polyvinyl pyrrolidone, carbopols, polyetylene oxides, magnesium1 aluminum silicate, modified starch derivatives or a derivative of such hydrophilic polymers and a combination thereof;
c) Hydrophobic non-degradable polymer selected from the group consisting of ethylcellulose, , polyethylene, polyamide, polyvinylchloride, polyvinyl acetate or mixtures thereof;
d) Natural gums like acacia, gum tragacanth, locust bean gum, guar gum, karaya gum, modified cellulosic, agar, pectin, carrageen, carboxypolymethylene, gelatin, casein, zein, bentonite,
e) The water insoluble polymers selected from the group consisting of, cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropyl methylcellulose phthalate and a combination thereof; 28
f) Stearic acid with other fatty acid esters of which are glyceryl monostearate, palmitic, behenic acid, glyceryl behenate, glyceryl palmitostearate, hydrogenated castor oil or other natural waxes etc.
9. An oral sustained release formulation according to claim 1 , wherein the ratio of drug to release retarding polymers is about 1 : 1 .
10. An oral sustained release composition according to claim 3, wherein the ratio of gas generating agent sodium bicarbonate to citric acid is about 1 :0.2 to 1 : 1 .
1 1. An oral sustained release composition according to claim 1 , is formulated by wet granulation or non aqueous granulation using solvent & binder.
12. An oral sustained release composition according to claim 1 and 3, wherein formulation comprises of diluents/compression aids and disintegrants selected from lactose, microcrystalline cellulose, dicalcium phosphate, sucrose, mannitol, xylitol, starch; lubricants selected from magnesium stearate, sodium stearyl fumarate and stearic acid, talc and colloidal silica; binders selected from natural gums, polyvinylpyrrolidone, starch preferably povidone flow aids such as silicon dioxide or talc.
13. The oral sustained release formulations according to claim 1 , are in form selected from tablet, capsule, granules or a sachet, typically a tablet, with or without coating, bi-layered tablet in combination with other drugs, as a combination kit of sustained release dosage forms.
14. The oral sustained release formulations as claimed in claim 13 are in form selected from functional coated tablets or caplets, or time- release tablets or caplets, floating tablets, matrices containing wax or polymer, controlled release beads, granules, spheroids that are contained within a capsule or administered from a sachet or other unit dose powder device to mammals.
15. A process for preparing an oral sustained release formulation according to any of claims 2, 3 or 14, wherein the tablets are optionally coated to get the elegant appearance by using suitable coating material selected from titanium dioxide, shellac, carbowax, sugar, etc. using aqueous or non-aqueous solvents.

29

STATEMENT UNDER ARTICLE 19

Present invention relates to oral gastro-retentive dosage forms comprising skeletal muscle relaxant which release active medicaments over period of 24 hours thereby achieving maximum absorption providing enhanced therapeutic effect in treatment of mucoskeletal disorders in mammals.

WO2009/013552 (D1) discloses tolperison hydrochloride containing pharmaceutical compositions with controllable release of active agent and process for preparation thereof. Controlled release pharmaceutical composition of D1 comprises multiple granule cores formed with natural anionic polymer and lipophilic excipient, hydrophilic matrix-forming excipient which surrounds the cores, and other pharmaceutically acceptable excipients. D1 does not specify the polymer systems used in the present invention to provide oral sustained release dosage form. The example 7 of D1 suggests that release test was carried for 8 hours and the same is also evident from figure 2. D1 clearly hints that 8 hour release is achieved. From the pattern of 80% in 8 hours, it cannot be speculated that rest of 20% release would be release for another 18 hours . or 16 hours. Neither there is any hint or teaching for therapeutic requirements in D1 for the drug release beyond 8 hours.

WO2004/032927 (D2), EP1 163902 (D3), US5252588 (D4) and EP 029541 1 (D5) relate to transdermal drug delivery systems which has different pharmacokinetics 30 than oral drug delivery route. None of these hints oral sustained release formulation with drug release upto 24 hour.

Accordingly claims 1 and its dependent claims are novel over D1 to D5.

D1 utilizes the formulation strategy as coating the granules with hydrogels which later are embedded in lipophilic excipients and finally compressed into tablet dosage form. The present process does not use such tedious, expensive and complicated procedures and is simple and easy to be industrially applied. Further D1 to D5 does not disclose oral sustained release formulations with drug release upto 24 hours. Accordingly claim 14 is novel. Further none of the prior art specifies the said coloring and coating for giving elegant appearance to the formulation as claimed in claim . Accordingly claim 18 is novel over prior art.

US2005/196451 (D6), an acknowledged prior art, utilizes different grades of Eudragit polymers for sustaining drug release upto 10 hours. D6 utilizes combinations of methacrylic acid polymers which are not cost effective. The release retardant polymers in D6 have different drug release pattern than polymers used in the present invention.

Accordingly prior art D1 to D6 does not motivate a person skilled in the art to arrive at a formulation with drug release upto 24 hours with judicial selection of polymers and its amounts employing simple process. Examples 15 to 19 discloses combinations of various polymer with actives in ratios 1 : 0.5 to 1 : 3, which gives the desired release profile. It is further submitted that claims are not characterized solely by release profile, rather they specify use of polymers in a defined ratio of 1 : 0.5 to 1 : 3.

However to emphasise the distinctness of present invention claims have been amended which may be regarded as amendment with Statement under Article 19.

PCT/IN2010/000137 2009-03-09 2010-03-09 A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants WO2010103544A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN2010800196712A CN102438597A (en) 2009-03-09 2010-03-09 A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants
EP10740754A EP2405900A2 (en) 2009-03-09 2010-03-09 A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants
EA201171109A EA201171109A1 (en) 2009-03-09 2010-03-09 NEW COMPOSITION OF THE DELAYED RELEASE OF COMPOUNDS SELECTED FROM THE CLASS OF MINORALEXANTS OF CENTRAL ACTION

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN522MU2009 2009-03-09
IN522/MUM/2009 2009-03-09

Publications (3)

Publication Number Publication Date
WO2010103544A2 WO2010103544A2 (en) 2010-09-16
WO2010103544A3 WO2010103544A3 (en) 2011-04-07
WO2010103544A4 true WO2010103544A4 (en) 2011-06-03

Family

ID=42728892

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2010/000137 WO2010103544A2 (en) 2009-03-09 2010-03-09 A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants

Country Status (5)

Country Link
EP (1) EP2405900A2 (en)
CN (1) CN102438597A (en)
EA (1) EA201171109A1 (en)
GE (1) GEP20135986B (en)
WO (1) WO2010103544A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2012157127A (en) 2010-07-06 2014-08-20 Навифарм. Ко., Лтд. PHARMACEUTICAL COMPOSITION CONTAINING DAPOXETINE FOR ORAL ADMINISTRATION WITH SLOW DELIVERY
WO2012172413A1 (en) 2011-06-16 2012-12-20 Abbott Healthcare Pvt. Ltd. Pharmaceutical composition comprising a combination of eperisone and diclofenac and process for preparing thereof
KR101156054B1 (en) * 2011-09-05 2012-06-20 주식회사 네비팜 A stable and control-released pharmaceutical composition comprising eperisone
KR101832842B1 (en) * 2012-01-13 2018-02-27 한미약품 주식회사 Pharmaceutical composition with an improved stability comprising eperisone or a pharmaceutically acceptable salt thereof and specific acidifying agent
EP2875359A4 (en) 2012-03-30 2015-08-19 Charles R Drew University Of Medicine And Science Compositions and methods for treating or preventing metabolic syndrome disorders
CN102895206A (en) * 2012-10-31 2013-01-30 中国药科大学 Rhizoma bletillae polysaccharide gastric-floating tablet and preparation method and application thereof
US20140271923A1 (en) 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
KR101497354B1 (en) * 2013-03-29 2015-03-02 초당약품공업 주식회사 Slow release pharmaceutical composition having Eperisone as active ingredient
CN103432093B (en) * 2013-08-31 2015-03-25 西南大学 Pridinol methanesulfonate matrix sustained-release tablet and preparation method thereof
ES2582878T3 (en) * 2013-09-12 2016-09-15 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical formulation comprising a combination of a muscle relaxant and an analgesic
PL2848260T3 (en) * 2013-09-12 2016-09-30 Novel formulations of thiocolchicoside
RS54912B1 (en) * 2013-09-12 2016-10-31 Sanovel Ilac Sanayi Ve Ticaret As Sustained release pharmaceutical formulations of thiocolchicoside
CN104688709A (en) * 2015-03-24 2015-06-10 北京世桥生物制药有限公司 Fumaric acid quetiapine composition sustained-release tablet and preparing method thereof
WO2018044020A1 (en) * 2016-08-29 2018-03-08 초당약품공업 주식회사 Method for preparing eperisone sustained release microsphere, and composite preparation of eperisone sustained release microsphere and aceclofenac
TR201720293A2 (en) 2017-12-13 2019-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Tolperisone and non-selective cox inhibitor combinations
TR201720289A2 (en) * 2017-12-13 2019-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Tolperizon and Selective COX-2 Inhibitor Combinations
TR201819202A2 (en) * 2018-12-12 2020-06-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A COMBINATION CONTAINING ONE MULTIPLE SCLEROSIS AGENT AND AT LEAST ONE MUSCLE RELAXING AGENT
TR201906487A1 (en) 2019-04-30 2020-11-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi PHARMACEUTICAL COMPOSITIONS CONTAINING TOLPERISONE AND NIMESULIDE COMBINATIONS

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0720866B2 (en) * 1987-05-15 1995-03-08 三生製薬株式会社 Transdermal preparation containing eperisone or tolperisone or their salts
JPS6485915A (en) 1987-09-28 1989-03-30 Eisai Co Ltd Hypotensor
US5252588A (en) * 1990-04-27 1993-10-12 Sekisui Kagaku Kogyo Kabushiki Kaisha Percutaneously absorbable crosslinked polyvinylpyrrolidone eperisone or tolperisone preparation
WO1992017166A1 (en) 1991-04-08 1992-10-15 Nippon Shinyaku Co., Ltd. Capsule
AT409083B (en) 1999-04-01 2002-05-27 Sanochemia Pharmazeutika Ag PHARMACEUTICAL PREPARATION CONTAINING TOLPERISON FOR ORAL ADMINISTRATION
US6753011B2 (en) 2000-01-14 2004-06-22 Osmotica Corp Combined diffusion/osmotic pumping drug delivery system
KR100433614B1 (en) * 2000-06-16 2004-05-31 주식회사 태평양 Transdermal Preparation Containing Hydrophilic or Salt-form Drug
US6733781B2 (en) 2000-12-06 2004-05-11 Wyeth Fast dissolving tablet
US20040224012A1 (en) 2001-10-05 2004-11-11 Pichit Suvanprakorn Topical application and methods for administration of active agents using liposome macro-beads
KR100511492B1 (en) * 2002-10-11 2005-08-31 주식회사 태평양 Transdermal preparations comprising eperisone, tolperisone or salts thereof
AT500144A1 (en) * 2004-03-05 2005-11-15 Sanochemia Pharmazeutika Ag TOLPERISON-CONTAINING PHARMACEUTICAL PREPARATION WITH CONTROLLABLE ACTIVE INGREDIENTS FOR ORAL ADMINISTRATION
US20060004050A1 (en) 2004-07-02 2006-01-05 Speicher Brian T Compositions and methods for the prevention or treatment of pain and other nervous system disorders
CN101002752A (en) * 2005-09-26 2007-07-25 刘凤鸣 Slow release preparation of tropyone
MX2008013437A (en) 2006-04-20 2009-03-06 Sanochemia Pharmazeutika Ag Method for administering tolperisone.
HUP0700485A3 (en) * 2007-07-23 2010-01-28 Richter Gedeon Nyrt Pharmaceutical composition with controlled release containing tolperisone

Also Published As

Publication number Publication date
WO2010103544A3 (en) 2011-04-07
EP2405900A2 (en) 2012-01-18
CN102438597A (en) 2012-05-02
EA201171109A1 (en) 2012-03-30
GEP20135986B (en) 2013-12-10
WO2010103544A2 (en) 2010-09-16

Similar Documents

Publication Publication Date Title
WO2010103544A4 (en) A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants
US8512748B2 (en) Controlled release system and method for manufacturing the same
ES2606463T3 (en) Combination of levodopa / carbidopa immediate release and controlled release dosage forms
TW201041608A (en) Orally disintegrating tablet compositions comprising combinations of high and low-dose drugs
WO2009034541A9 (en) Controlled release pharmaceutical dosage forms of trimetazidine
EP2043615A2 (en) Pharmaceutical compositions comprising levetiracetam
JP5948648B2 (en) Sustained release formulation containing stabilized eperisone
CA2742680C (en) Pharmaceutical compositions for release control of methylphenidate
ES2616115T3 (en) Oral controlled release pharmaceutical form comprising oxycodone
WO2010128525A4 (en) A formulation of ivabradine for treating the cardiovascular disease
KR20090029830A (en) Pharmaceutical preparation for oral administration with controlled active ingredient release in the small intestine and methods for its production
IL224230A (en) Formulations containing nalbuphine and uses thereof
WO2012101653A2 (en) Modified release pharmaceutical compositions memantine
CA2860098A1 (en) Immediate release multi unit pellet system
US20130323309A1 (en) Sustained Release Composition of Memantine
WO2014167440A1 (en) Modified release pharmaceutical compositions of cyclobenzaprine or salts thereof
ES2336215T3 (en) PHARMACEUTICAL COMPOSITIONS OF MODAFINIL WITH MODIFIED RELEASE.
EP2603207A2 (en) Oral controlled release pharmaceutical compositions of blonanserin
WO2010023690A2 (en) Prolonged release formulation of amisulpride
JP2003055199A (en) Sustained release micropellet
JP2010511023A (en) Memantine formulation
ES2317450T3 (en) FORMULATION OF CONTROLLED RELEASE OF VALPROIC ACID AND ITS DERIVATIVES.
WO2014003371A1 (en) Immediate-release and sustained-release pharmaceutical composition comprising acebrophylline
ES2697609T3 (en) Pharmaceutical composition containing an antimuscarinic agent and method for the preparation thereof
JP2009525953A (en) Sustained release formulation of divalproic acid and its derivatives

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080019671.2

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12011501791

Country of ref document: PH

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10740754

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 12409

Country of ref document: GE

Ref document number: a201111780

Country of ref document: UA

Ref document number: 201171109

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2010740754

Country of ref document: EP